The number of people with susceptibility test result for rifampicin in Peru

Peru: The number of people with susceptibility test result for rifampicin was 13,453 in 2021. ▼ Falling

Latest (2021)
13,453
Change on year
up 40.4%
World rank
18th
of 155 countries
All-time high
14,261
in 2017
All-time low
9,583
in 2020
Years of data
5
2017–2021

The number of people with susceptibility test result for rifampicin in Peru, 2017–2021

05.0k10.0k15.0k2017201920212017: 14.3k2018: 12.8k2019: 13.4k2020: 9.6k2021: 13.5k

Source: World Health Organization, Global Health Observatory.

Analysis

Peru recorded 13,453 for the number of people with susceptibility test result for rifampicin in 2021.

The figure is up 40.4% on the previous year and down 5.7% over five years.

Peru ranks 18th of 155 countries on this measure, in the top quarter.

The number of people with susceptibility test result for rifampicin in Peru, year by year

Annual values for The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients. in Peru, 2017 to 2021.
Year Value Change
2017 14,261
2018 12,771 -10.4%
2019 13,424 +5.1%
2020 9,583 -28.6%
2021 13,453 +40.4%

Peru compared with similar countries

  • Peru's 13,453 is above the median for upper middle income countries, which is 880, 15.3× the median. (46 countries reporting)
  • Peru's 13,453 is above the median for Latin America & Caribbean, which is 406.5, 33.1× the median. (26 countries reporting)

Averages by decade

DecadeAverage LowestHighest Years
2010s 13,485 12,771 14,261 3
2020s 11,518 9,583 13,453 2

Countries ranked near Peru

  1. 15 Russian Federation 21,391 compare
  2. 16 Afghanistan 17,443 compare
  3. 17 Zambia 16,922 compare
  4. 19 Nepal 11,863 compare
  5. 20 Malaysia 10,434 compare
  6. 21 Angola 10,250 compare

See the full ranking of 157 places →

More health data for Peru

All data for Peru →

Frequently asked questions

What is the number of people with susceptibility test result for rifampicin in Peru?
The number of people with susceptibility test result for rifampicin in Peru was 13,453 in 2021, according to World Health Organization, Global Health Observatory.
What is the highest the number of people with susceptibility test result for rifampicin recorded in Peru?
The highest recorded value was 14,261 in 2017.
What is the lowest the number of people with susceptibility test result for rifampicin recorded in Peru?
The lowest recorded value was 9,583 in 2020.
How does Peru rank for the number of people with susceptibility test result for rifampicin?
Peru ranks 18th out of 155 countries with data for 2021.
Where does this Peru data come from?
The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).

Share, cite or embed this page

Cite this page

The number of people with susceptibility test result for rifampicin in Peru. Statizoid, drawing on World Health Organization, Global Health Observatory. Retrieved 13 September 2026, from https://health.statizoid.com/stat/the-number-of-people-with-susceptibility-test-result-for-rifampicin-among/peru/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY-NC-SA 3.0 IGO (WHO); please keep the attribution.

<a href="https://health.statizoid.com/stat/the-number-of-people-with-susceptibility-test-result-for-rifampicin-among/peru/">The number of people with susceptibility test result for rifampicin in Peru</a> — Statizoid

About this data

Indicator
The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.
Source
World Health Organization, Global Health Observatory
Licence
CC BY-NC-SA 3.0 IGO (WHO)
Coverage
157 places, 785 data points, 2017–2021
Last refreshed